Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply

Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details remain unclear.

CNBC • Jul 22, 2026

Mylan to sell up to $363 million stake in India's Biocon, term sheet shows

Mylan ​Inc plans ‌to sell up ​to ​92 million shares ⁠in ​Indian ​drugmaker Biocon Ltd , worth ​up ​to 34.81 billion ‌Indian ⁠rupees ($363 million), according to ​a ​term ⁠sheet seen ​by ​Reuters.

Reuters • Jul 13, 2026

Why Viatris (VTRS) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jul 10, 2026

Should Value Investors Buy Viatris (VTRS) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Jul 9, 2026

VTRS or DHR: Which Is the Better Value Stock Right Now?

Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Jul 9, 2026

3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now

Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance.

24/7 Wall Street • Jul 7, 2026

Viatris (VTRS) is a Great Momentum Stock: Should You Buy?

Does Viatris (VTRS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Jul 2, 2026

Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026

PITTSBURGH, July 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report second-quarter 2026 financial results on Thursday, August 6, 2026. Company executives will host a conference call and live webcast at 8:30 a.m.

PRNewsWire • Jul 1, 2026

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies  Japanese New Drug Application Submission Targeted by End of 2026 PITTSBURGH and TOKYO, June 29, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of VR-205 (targeted-release budesonide formulation) (Nefecon®) in Japanese adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of developing end-stage renal disease. The Phase 3 clinical trial was a multicenter, interventional, open-label study designed to evaluate the efficacy and safety of 16 mg of VR-205 in Japanese adult patients with primary IgAN.

PRNewsWire • Jun 29, 2026

Here's Why Viatris (VTRS) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jun 29, 2026